Evaluating outcomes and quality of life for patients on ECMO

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the outcomes and quality of life for patients undergoing extracorporeal membrane oxygenation (ECMO) therapy for severe respiratory or cardiocirculatory failure. It will compare healthcare providers' estimated outcomes with actual patient results to better understand the effectiveness of ECMO treatment. The study focuses on long-term implications of ECMO, particularly regarding quality of life after hospital discharge, which has been insufficiently studied. By gathering data on patient-centered outcomes, the research seeks to improve decision-making processes in emergency ECMO situations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age ≥ 18 years
* start of ECMO therapy ≤24h
* written informed consent from patient or health-care proxy

Exclusion Criteria:

* age \< 18 years
* Language barrier (communication in German/local language or English not possible).
* no ECMO therapy or ECMO therapy longer than 24h
* no written consent

Where it's running

• University Hospital Duesseldorf
  Düsseldorf, North Rhine-Westphalia, Germany Recruiting

Study contacts

• Principal investigator: René M'Pembele, MD — Heinrich-Heine University, Duesseldorf
• Study coordinator: René M'Pembele, MD
• Email: rene.mpembele@med.uni-duesseldorf.de
• Phone: 02118118451

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Impact of lower vasopressor use on survival in patients with heart failure on ECMO

  This study is testing if using less vasopressor medication can help adults with heart failure on ECMO survive better over 30 days.

  Recruiting Beijing Anzhen Hospital · Beijing, Beijing Municipality · NCT06862700

• Nebulized amikacin for VA-ECMO–associated pneumonia in adults

  We’re testing whether giving amikacin as a nebulized inhaled medicine helps clear gram-negative pneumonia in adults on VA-ECMO who are also on mechanical ventilation.

  Recruiting Phase 2 Assistance Publique - Hôpitaux de Paris · Paris · NCT06602557

• Comparing blood transfusion thresholds in patients on ECMO

  This study tests whether giving fewer blood transfusions is safe and effective for adults on ECMO compared to giving more transfusions.

  Recruiting at 13 sites Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Vienna, State of Vienna and 13 other locations · NCT06560164

• Evaluating the impact of transpulmonary mechanical power on patients with severe ARDS on ECMO

  This study is trying to see if measuring the power of breathing machines can help doctors predict how well patients with severe lung problems on ECMO will do and improve their treatment.

  Recruiting Beijing Chao Yang Hospital · Beijing, Beijing Municipality · NCT06062212

• Comparing individualized and conventional blood transfusion strategies during ECMO for heart failure

  This study is testing whether a personalized blood transfusion approach during heart support treatment can help patients use less blood and have better outcomes compared to the standard method.

  Recruiting at 4 sites Phase 1 University Hospital, Lille · Lille, NORD and 3 other locations · NCT05699005

• Testing inhaled hydrogen gas for cardiac arrest treatment

  This study is testing if breathing in hydrogen gas can help improve recovery for patients who have had a cardiac arrest and are receiving special life-saving treatment.

  Recruiting Phase 1 Boston Children's Hospital · Washington D.C., District of Columbia and 3 other locations · NCT05574296

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.